Figure 4
Figure 4. PI3K/AKT, p38MAPK, Rho-kinase, and NF-κB participate differently in the chemotaxis of mock- and BAFF-treated B cells. Mock-treated (□) and BAFF-treated (▫) B cells from 6 different donors were incubated for 1 hour at 37°C with various inhibitors or DMSO and were then subjected to the chemotaxis assay to 500 ng/mL CXCL13 (A) or 250 ng/mL CCL21 (B). Results are expressed as the mean percentage of inhibition plus or minus SD of the specific migration. *P < .05; **P < .005. B cells from 3 different donors were incubated with medium, 100 nM WM, 10 μM SB203580, or both in the presence (▫) or absence (□) of 25 ng/mL BAFF for 16 hours at 37°C and were then subjected to the chemotaxis assay to 500 ng/mL CXCL13 (C) or 250 ng/mL CCL21 (D). Results are expressed as the mean percentage plus or minus SD of specific migration.

PI3K/AKT, p38MAPK, Rho-kinase, and NF-κB participate differently in the chemotaxis of mock- and BAFF-treated B cells. Mock-treated (□) and BAFF-treated (▫) B cells from 6 different donors were incubated for 1 hour at 37°C with various inhibitors or DMSO and were then subjected to the chemotaxis assay to 500 ng/mL CXCL13 (A) or 250 ng/mL CCL21 (B). Results are expressed as the mean percentage of inhibition plus or minus SD of the specific migration. *P < .05; **P < .005. B cells from 3 different donors were incubated with medium, 100 nM WM, 10 μM SB203580, or both in the presence (▫) or absence (□) of 25 ng/mL BAFF for 16 hours at 37°C and were then subjected to the chemotaxis assay to 500 ng/mL CXCL13 (C) or 250 ng/mL CCL21 (D). Results are expressed as the mean percentage plus or minus SD of specific migration.

Close Modal

or Create an Account

Close Modal
Close Modal